BACKGROUND: The changes in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However, it has remained difficult to differentiate between NASH and nonprogressive NAFLD by clinical examination. We investigated the interrelationships between serum high-sensitivity C-reactive protein (hs-CRP) and the pathogenesis and progression of NASH. METHODS: Hs-CRP was measured in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), and a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to measure the intrahepatic mRNA expressions of CRP and interleukin (IL)-6. RESULTS: The results of a multiple regression analysis revealed that in comparison with cases of steatosis, hs-CRP was significantly elevated (P = 0.0048) in cases of NASH. Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. The results of the RT-PCR analysis showed that intrahepatic mRNA expression of CRP, but not IL-6, was increased in patients with NASH compared with those with steatosis (P = 0.0228). CONCLUSIONS: This is the first report to demonstrate consistent and profound elevation of hs-CRP in cases of NASH compared with in cases of simple nonprogressive steatosis. Our results suggest that hs-CRP may be a clinical feature that not only distinguishes NASH from simple nonprogressive steatosis but also indicates the severity of hepatic fibrosis in cases of NASH.
BACKGROUND: The changes in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However, it has remained difficult to differentiate between NASH and nonprogressive NAFLD by clinical examination. We investigated the interrelationships between serum high-sensitivity C-reactive protein (hs-CRP) and the pathogenesis and progression of NASH. METHODS: Hs-CRP was measured in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), and a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to measure the intrahepatic mRNA expressions of CRP and interleukin (IL)-6. RESULTS: The results of a multiple regression analysis revealed that in comparison with cases of steatosis, hs-CRP was significantly elevated (P = 0.0048) in cases of NASH. Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. The results of the RT-PCR analysis showed that intrahepatic mRNA expression of CRP, but not IL-6, was increased in patients with NASH compared with those with steatosis (P = 0.0228). CONCLUSIONS: This is the first report to demonstrate consistent and profound elevation of hs-CRP in cases of NASH compared with in cases of simple nonprogressive steatosis. Our results suggest that hs-CRP may be a clinical feature that not only distinguishes NASH from simple nonprogressive steatosis but also indicates the severity of hepatic fibrosis in cases of NASH.
Authors: W Koenig; M Sund; M Fröhlich; H G Fischer; H Löwel; A Döring; W L Hutchinson; M B Pepys Journal: Circulation Date: 1999-01-19 Impact factor: 29.690
Authors: Seung H Park; Woo K Jeon; Sang H Kim; Hong J Kim; Dong I Park; Yong K Cho; In K Sung; Chong I Sohn; Dong K Keum; Byung I Kim Journal: J Gastroenterol Hepatol Date: 2006-01 Impact factor: 4.029
Authors: John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust Journal: J Hepatol Date: 2006-03-20 Impact factor: 25.083
Authors: Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George Journal: Hepatology Date: 2004-07 Impact factor: 17.425
Authors: Seung Ha Park; Byung Ik Kim; Jung Won Yun; Jeong Wook Kim; Dong Il Park; Yong Kyun Cho; In Kyung Sung; Chang Young Park; Chong Il Sohn; Woo Kyu Jeon; Hyang Kim; Eun Jung Rhee; Won Young Lee; Sun Woo Kim Journal: J Gastroenterol Hepatol Date: 2004-06 Impact factor: 4.029
Authors: Fabiola Rabelo; Claudia P M S Oliveira; Joel Faintuch; Daniel F C Mazo; Vicencia M R Lima; Jose Tadeu Stefano; Hermes V Barbeiro; Francisco G Soriano; Venancio A Ferreira Alves; Flair J Carrilho Journal: Obes Surg Date: 2010-07 Impact factor: 4.129
Authors: Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Giacomo Zoppini; Michel Chonchol Journal: Clin J Am Soc Nephrol Date: 2010-08-19 Impact factor: 8.237
Authors: Kristin M Hirahatake; Richard S Bruno; Bradley W Bolling; Christopher Blesso; Lacy M Alexander; Sean H Adams Journal: Adv Nutr Date: 2020-03-01 Impact factor: 8.701
Authors: L Maria Belalcazar; George D Papandonatos; Bahar Erar; Inga Peter; Hadeel Alkofide; Ashok Balasubramanyam; Ariel Brautbar; Steven E Kahn; William C Knowler; Christie M Ballantyne; Jeanne M McCaffery; Gordon S Huggins Journal: Circ Cardiovasc Genet Date: 2015-11-17